Di Tanna, Gian Luca
Bychenkova, Anna
O’Neill, Frank
Wirtz, Heidi S.
Miller, Paul
Ó Hartaigh, Briain
Globe, Gary
Funding for this research was provided by:
Amgen
Article History
First Online: 31 December 2018
Compliance with Ethical Standards
:
: This study was funded by Amgen, GmbH, Zug, Switzerland. Neither honoraria nor payments were provided for authorship.
: GL Di Tanna, A Bychenkova, H Wirtz, and G Globe are employees of Amgen and may hold corporate stock in Amgen. H Wirtz also holds corporate stock in Teva Pharmaceutical Industries Ltd. F O’Neill was an employee of Amgen until April 2018. P Miller has previously consulted for AstraZeneca, GSK, Pfizer, Novartis, Roche, Chiesi, and Bayer. B Ó Hartaigh was an employee of Curo, part of the Envision Pharma Group, when the study was conducted, who was contracted by Amgen to provide editorial support in the preparation of this manuscript.
: For this type of study, formal consent is not required.
: Data sharing is not applicable to this article as no datasets were generated or analysed during the current review.